WuXi Biologics (HKEX: 2269), today announced a definitive agreement with Merck & Co’s (NYSE: MRK) MSD International GmbH unit, whereby the latter will acquire WuXi Vaccines’ facility in Dundalk, ...
WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...
A Chinese pharmaceutical company expects to hire up to 500 employees for the first phase of its new campus in northern ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen, used on ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback